Jushi Biotech's SYS6010 drug, a subsidiary of New Novus (300765.SZ), was included in the list of breakthrough treatment varieties

Zhitong Finance App News, Xinnovo (300765.SZ) announced that the company's holding subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd. (“Jushi Bio”) drug SYS6010 (anti-human EGFR humanized monoclonal antibody-JS-1 conjugate injection) was included in the list of breakthrough treatments by the Drug Evaluation Center of the China Drug Administration (“Drug Review Center”).

SYS6010 (anti-human EGFR humanized monoclonal antibody-JS-1 conjugate injection) developed by Jushi Biotech was granted breakthrough treatment certification by the Drug Review Center. The proposed indication is for use as a single agent for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) that has failed to be treated with EGFR-TKI and platinum-containing chemotherapy.